Market News
Smart Trading. Simplified.
Get FREE Trade Alerts from Top Stock Research Firm (No Credit Card Needed)
Ken Berman, founder of Gorilla Trades, has announced that Gorilla Trades will offer 30 days of FREE trade alerts to investors around the world. "I believe retail investors can manage their own money if they use a proven trading system like mine. Once they see how easy it is, they will be hooked," he said. The daily alerts will be given using the Breakout Scanner, software Ken used to turn $250,000 into $5,000,000.
Is IGT Stock A Buy?
International Game Technology PLC (NYSE:IGT) is a London, U.K.-based gaming technology company that makes slow machines and other gambling-based products and services. The gaming industry was hit especially hard travel restrictions; it’s highly dependent on tourism. Now that travel is picking back up, is IGT stock a Buy? The company has a lot of solid […]
Early Profit-Advantage On Wall Street's Hidden Uranium Stock
Uranium prices are soaring as more than HALF of global monthly uranium production has been taken offline as mines shut down amid the coronavirus pandemic. Investors are lining up for gains and it could be the windfall of a lifetime. The last time we saw something like this, the price of yellowcake roared all the way to $140. Well-timed investors could make 10X, 20X and even 30X gains!
3 Top Weed Stocks To Buy Now
Harvest Health & Recreation Inc. (HRVSF) Shares in Harvest Health & Recreation have been trading higher on news that the cannabis dispenser is to be acquired by competitor Trulieve (TCNNF) in what will be the largest US cannabis takeover to date. If the merger goes ahead, the transaction will result in the most profitable multi-state […]
Jeff Bezos' Next Big Thing
The tech visionary who built a revolutionary $1.6 trillion company from scratch is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
Alphabet Stock Vs Google Stock?
Alphabet Stock vs Google Stock: Google might have started as a basic search engine when it launched in 1997, but it has evolved into a tool that most internet users consider essential to their digital lifestyle. That was made abundantly clear in 2006 when the word “Google” was added to the Oxford English Dictionary. Google […]
Investors Get Green-Light on US$0.25 Per Share Uranium Stock
Uranium prices are on a tear amid global mine shutdowns in the face of the coronavirus pandemic which has now forced nearly 50% of global uranium production offline. Select US uranium stocks are poised to deliver big gains to investors. Here's a little-known company that has quietly amassed over 45 million lbs of high-grade uranium resources - all on US soil - and trading below US$0.25 per share.
Will Boeing Stock Recover?
Will Boeing Stock Recover? For some of the investors who like established blue-chip companies in comfortable industries, there’s been nothing better than Boeing, which sits in between commercial airline services and Defense Department contracting. However, that narrative has unraveled over the past year and a half, leading traders to ponder: “should I buy (or sell) […]
The End of Alzheimer's?
Jeff Bezos is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's. Goldman Sachs & a Big Pharma giant have invested billions into this small biotech.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
NIO Stock Forecast
NIO Inc. [NYSE: NIO] is a Chinese multinational automobile manufacturer which designs, develops, manufactures, and sells fully electric, battery-powered vehicles in Mainland China, and Hong Kong among other countries. NIO produces five, six, and seven-seater electric SUVs, as well as smart electric sedans. The company also offers comprehensive value-added services, and a convenient and innovative […]
The World's First $20 Trillion Drug?
One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
Our research shows that anyone who gets in by June 2, 2021 could turn every $1,000 into $1.1 million.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment